Results 201 to 210 of about 1,128,571 (299)

Leptin Receptor Fibroblasts Are Preferential Contributors to Cardiac Fibrosis. [PDF]

Circ Res
Larcher V, Fischer A, Zhang L, Almolla O, Chiesa M, Andriani F, Wernet C, Serio S, Tombor LS, Peruzzo S, Mukherjee D, Bussani R, Zacchigna S, Adams RH, Dimmeler S, Evans SM, Cattaneo P, Guimarães-Camboa N.   +17 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Exposure to TBBPA and polystyrene nanoplastics induces cardiac fibrosis via the activation of the ESR/H19/Wnt pathway. [PDF]

Redox Biol
Pei XY, Wang XR, Liu SY, Cheng MD, Li CL, Li S, Xu HM, Zhang YF.   +7 more
europepmc   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

Targeting ADAMTS1/HDAC6 alleviates TGF-β1/SMAD2-associated cardiac fibrosis in cardiac fibrosis post-myocardial infarction. [PDF]

Cell Biol Toxicol
Jin Q, Chen C, Wu P, Li L, Jiang L, Chen R, Xu S, Huang Y, Xu H, Long X.   +9 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Correction to "S100A9 Aggravates Cardiac Fibrosis by TLR4/PGC-1α Mediated Macrophage-Myofibroblast Crosstalk". [PDF]

J Extracell Vesicles
europepmc   +1 more source

PCPE-1 promotes cardiac fibrosis with aging and obesity. [PDF]

JCI Insight
Hsiao YT, Yoshida Y, Tsuchimochi H, Tang J, Aung TM, Chang CH, Barinda AJ, Li Z, Othman NSB, Yoshizaki T, Ling Y, Okuda S, Abe M, Mizuno S, Takahashi S, Inomata T, Kioka H, Sakata Y, Maeda D, Matsue Y, Furihata T, Iwata H, Pearson JT, Otsu K, Walsh K, Ishigami A, Minamino T, Shimizu I.   +27 more
europepmc   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

VAP1 promotes cardiac fibrosis by enabling PDGFR signaling in myofibroblasts. [PDF]

Exp Mol Med
Huang S, Zhao Q, Shao T, Zhu C, Xue Y, Chen N, Zhang Y, Xu H, Kong M, Wang R.   +9 more
europepmc   +1 more source